{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:37:16Z","timestamp":1791434236818,"version":"4.3.3"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.eururo.2014.02.040","type":"journal-article","created":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T05:31:00Z","timestamp":1393392660000},"page":"502-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma"],"prefix":"10.1016","volume":"66","author":[{"given":"Rana R.","family":"McKay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia J.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.C.","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Simantov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.02.040_bib0005","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2014.02.040_bib0010","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.02.040_bib0015","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.040_bib0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.eururo.2014.02.040_bib0025","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2014.02.040_bib0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2013.08.012","article-title":"Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy","volume":"65","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.02.040_bib0035","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.040_bib0040","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.02.040_bib0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.26034","article-title":"Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function","volume":"130","author":"Maita","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2014.02.040_bib0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-011-1721-x","article-title":"Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999\u20132006","volume":"131","author":"Sathiakumar","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.eururo.2014.02.040_bib0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999\u20132006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2014.02.040_bib0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3111\/13696998.2011.649324","article-title":"Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers","volume":"15","author":"Henk","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.eururo.2014.02.040_bib0065","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2014.02.040_bib0070","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.040_bib0075","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.040_bib0080","first-page":"1099","article-title":"A systematic review of bisphosphonate osteonecrosis (BON) in cancer","volume":"18","author":"Migliorati","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eururo.2014.02.040_bib0085","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2014.02.040_bib0090","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Smidt-Hansen","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.eururo.2014.02.040_bib0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/cncr.22827","article-title":"Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy","volume":"110","author":"Choueiri","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.02.040_bib0100","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.02.040_bib0105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/annonc\/mdq342","article-title":"Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma","volume":"22","author":"Patil","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2014.02.040_bib0110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/COC.0b013e3181574084","article-title":"Sorafenib for metastatic renal cancer: the Princess Margaret experience","volume":"31","author":"Riechelmann","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.040_bib0115","unstructured":"Vrdoljak E, Szczylik C, Mardiak J, et al. Use of bisphosphonates in combination with sunitinib in renal cell cancer patients with bone metastases from the expanded access study. Abstract 2756 presented at: European Cancer Congress; September 30, 2013; Amsterdam, The Netherlands."},{"key":"10.1016\/j.eururo.2014.02.040_bib0120","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2012.02.050","article-title":"Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma","volume":"48","author":"Keizman","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2014.02.040_bib0125","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2014.02.040_bib0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10585-011-9379-7","article-title":"Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis","volume":"28","author":"Yuasa","year":"2011","journal-title":"Clin Exp Metastasis"},{"issue":"Suppl 6","key":"10.1016\/j.eururo.2014.02.040_bib0135","first-page":"402","article-title":"RAD001 and zoledronic acid in patients with renal cell carcinoma with bone metastases (RAZOR): a randomized phase II trial","volume":"31","author":"Broom","year":"2013","journal-title":"ASCO Meeting Abstracts"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814001699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814001699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:03:10Z","timestamp":1759582990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283814001699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0302283814001699"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.02.040","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.02.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}